Abstracts tagged "Epidemiology"

Abstract Number: 1715 • ACR Convergence 2024
Mortality Trends for Systemic Connective Tissue Diseases Across the United States from 1999 to 2020: A CDC-Wonder Database Analysis
Naima Khan¹, Yumna Furqan², Madiha Salman¹, Eman Ali¹, Wajeeh ur Rehman³, Ibtesam Allahi⁴, Farah Yasmin⁵ and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Texas A&M School of Medicine, Dallas, TX, ³University Health Services Hospital, Johnson, NY, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Yale University School of Medicine, New Haven, CT 06511, U.S.A., New Haven, CT, ⁶AdventHealth, Sebring, FL
Background/Purpose: The mortality burden of systemic connective tissue diseases (CTDs) is expected to rise in the U.S population because of multimorbidity and ageing. The primary…
Abstract Number: 1890 • ACR Convergence 2024
Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study
Dani Contreras¹, Zanir Bhanji¹, J. Antonio Avina-Zubieta², Claire Barber¹ and Cheryl Barnabe¹, ¹University of Calgary, Calgary, AB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Ambulatory Care Sensitive Conditions (ACSCs) are conditions where appropriate access to ambulatory care could prevent or reduce complications, a more severe disease course, or…
Abstract Number: 1998 • ACR Convergence 2024
Association Between Small Interfering RNA Therapy and Autoimmune Diseases: U.S. Prospective Cohort Study
Liang Sien Chen, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, Taoyuan, Taiwan (Republic of China)
Background/Purpose: Monoclonal antibody (mAb) therapy and small interfering RNA (siRNA) therapy represent two cutting-edge approaches in treating various diseases, such as hyperlipidemia. Our study aims…
Abstract Number: 2413 • ACR Convergence 2024
The Natural History of SLE Has Changed Since the 1970s
Adaobi Ugochukwu¹, Daniel Goldman², Andrea Fava³, Laurence Magder⁴ and Michelle Petri², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: We investigated the changes in the prevalence of specific SLE manifestations over the last 50 years. In addition, we looked for differences between African-Americans…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 0157 • ACR Convergence 2024
Knowledge and Attitudes About Delta-9-tetrahydrocannabinol (THC) Impact Real-world Practice in an International Group of Rheumatologists
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center Consultant to ForWard, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists care for difficult to manage chronic diseases, necessitating adjustments to new treatments and evolving patient views. When making treatment decisions, rheumatologists incorporate clinical…
Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Priyanka Yalamanchili¹, Lydia Lee², Greta Bushnell³, Melissa Mannion⁴, Chintan Dave⁵ and Daniel B. Horton⁶, ¹Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Morris Plains, NJ, ²Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, NJ, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ, ⁶Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…
Abstract Number: 0677 • ACR Convergence 2024
Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Gulsen Ozen¹, Sofia Pedro², Kaleb Michaud³ and Robyn Domsic⁴, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…
Abstract Number: 0989 • ACR Convergence 2024
Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis
Mark Gibson¹, Benjamin Zuckerman², Maryam Adas¹, Mark Russell³, Katie Bechman¹ and James Galloway⁴, ¹King's College London, London, United Kingdom, ²King's College London, London, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
Abstract Number: 1081 • ACR Convergence 2024
Evaluation of Methods for Ascertainment and Categorization of Race and Ethnicity for Clinical Research: An Umbrella Review
Teresa Semalulu¹, Melanie Anderson², Shahad Al-Matar¹, SADEEM ALFRAIH¹, Azza Eissa³, Emma Neary⁴, Fadi Kharouf⁵, Abimbola Saka³, Zayd Schafer⁶, Zahi Touma¹ and Sindhu Johnson⁷, ¹University of Toronto, Toronto, ON, Canada, ²The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴McGill University, Montreal, QC, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶American University of Antigua, Saint John's, ⁷Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Race and ethnicity are increasingly evaluated in rheumatology research due to their influence on health outcomes, yet there remains heterogeneity in their interpretation and…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 1720 • ACR Convergence 2024
Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease
Justin Gatwood¹, Yong Zhu², Andrea Steffens², Stephanie Gallagher², Mary DuCharme² and Nikita Stempniewicz¹, ¹GSK, Philadelphia, PA, ²Optum Life Sciences, Eden Prairie, MN
Background/Purpose: Previous studies have demonstrated that the risk of herpes zoster (HZ) among adults with rheumatic disease, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA),…
Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Rutvin Kyada¹, Jean Liew², Maureen Dubreuil³, Matthew Brown⁴, Mariko Ishimori⁵, John Reveille⁶, Michael Ward⁷, Michael Weisman⁸ and Lianne S Gensler⁹, ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁴King's College London, London, United Kingdom, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston, ⁷NIH, Bethesda, MD, ⁸Stanford University, Los Angeles, CA, ⁹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…
Abstract Number: 2031 • ACR Convergence 2024
A Contemporary Assessment of the Burden of Malignancy in IgG4-Related Disease
Grace McMahon¹, Isha Jha¹, Guy Katz¹, Cory Perugino¹, Ana Fernandes¹, John Stone² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital , Harvard Medical School, Concord, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder that can affect nearly any organ. Because of the often tumefactive nature of IgG4-RD and its typical…
Abstract Number: 2421 • ACR Convergence 2024
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Mariana Gonzalez-Trevino¹, Jaime Flores Gouyonnet¹, Qiping Xu², Cassondra Hulshizer³, Jose Meade-Aguilar⁴, Erika Navarro-Mendoza¹, Mario Bautista-Vargas⁵, Gabriel Figueroa-Parra⁶, Alain Sanchez-Rodriguez⁷, Maria Cuellar-Gutierrez¹, Andrew C. Hanson⁸, Cynthia Crowson¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Health System - Mankato, Mankato, MN, ³Mayo Clinic, Utica, MN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁷Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸Mayo Clinic, Rochester
Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].